Endocrine therapy and urogenital outcomes among women with a breast cancer diagnosis
| Autor: | Carey K. Anders, Hazel B. Nichols, Suzanne N. Landi, Jennifer M. Wu, Kemi M. Doll, Laura H. Hendrix, Jeannette T. Bensen |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Breast Neoplasms Urinary incontinence Article 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine Epidemiology Prevalence medicine Humans 030212 general & internal medicine Aromatase Aged biology Aromatase Inhibitors business.industry Genitourinary system Middle Aged medicine.disease Sexual Dysfunction Physiological Tamoxifen Urinary Incontinence 030220 oncology & carcinogenesis Cohort biology.protein Female medicine.symptom business Sexual function medicine.drug |
| Zdroj: | Cancer Causes & Control. 27:1325-1332 |
| ISSN: | 1573-7225 0957-5243 |
| DOI: | 10.1007/s10552-016-0810-x |
| Popis: | Endocrine therapy for breast cancer can exacerbate menopausal symptoms. The association between endocrine therapy and common pelvic floor disorders including urinary incontinence has rarely been evaluated. We examined urogenital and sexual side effects among women with a breast cancer diagnosis, comparing endocrine therapy users to nonusers. Urogenital and sexual symptoms were self-reported during the enrollment interview within the University of North Carolina Cancer Survivorship Cohort. Tumor characteristics and endocrine therapy use were collected from medical and prescription records. We calculated multivariable prevalence ratios (PR) and 95 % confidence intervals (CI) for the association of endocrine therapy (versus no endocrine therapy) and urinary incontinence, overall and by therapy type (tamoxifen or aromatase inhibitors). PROMIS Sexual Function and Satisfaction domain scores were compared across endocrine therapy groups. Among the 548 women with a breast cancer diagnosis, 49 % received endocrine therapy. Overall, 18 % of women reported urinary incontinence symptoms. We observed no association between urinary incontinence and endocrine therapy use overall (PR = 0.97; 95 % CI 0.67, 1.43), tamoxifen (PR = 1.20; 95 % CI 0.74, 1.96), or aromatase inhibitors (PR = 0.89; 95 % CI 0.55, 1.42), compared to no use. Approximately 55 % of women were sexually active. Sexual function scores did not vary according to endocrine therapy use, although urinary incontinence was associated with lower satisfaction scores (p = 0.05). Our findings demonstrate a high prevalence of urinary incontinence after breast cancer diagnosis similar to the overall prevalence in older U.S. women, and this did not vary strongly according to use of endocrine therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink